AstraZeneca plc (AZN) Given Buy Rating at Deutsche Bank AG

Deutsche Bank AG reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Friday morning, Marketbeat reports. The brokerage currently has a GBX 5,700 ($75.19) price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the stock. Citigroup Inc. restated a buy rating and issued a GBX 6,000 ($79.15) price objective on shares of AstraZeneca plc in a research report on Thursday, July 13th. Barclays PLC restated an overweight rating and issued a GBX 6,000 ($79.15) price objective on shares of AstraZeneca plc in a research report on Friday, April 28th. HSBC Holdings plc cut shares of AstraZeneca plc to a reduce rating and set a GBX 4,500 ($59.36) price objective on the stock. in a research report on Friday, April 7th. Jefferies Group LLC cut shares of AstraZeneca plc from a buy rating to a hold rating and decreased their price objective for the company from GBX 5,350 ($70.57) to GBX 5,050 ($66.61) in a research report on Monday, April 10th. Finally, Shore Capital restated a sell rating on shares of AstraZeneca plc in a research report on Thursday, April 27th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. AstraZeneca plc presently has an average rating of Hold and a consensus price target of GBX 5,046.95 ($66.57).

Shares of AstraZeneca plc (LON:AZN) opened at 4571.00 on Friday. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The firm’s 50-day moving average is GBX 5,140.37 and its 200-day moving average is GBX 4,864.62. The company’s market cap is GBX 57.87 billion.

COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (AZN) Given Buy Rating at Deutsche Bank AG” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/2783341/astrazeneca-plc-azn-given-buy-rating-at-deutsche-bank-ag.html.

The company also recently announced a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be paid a GBX 68.90 ($0.91) dividend. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.35%.

In other news, insider Nazneen Rahman bought 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were purchased at an average price of GBX 4,370 ($57.64) per share, for a total transaction of £1,704.30 ($2,248.12).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.